Vitestro Raises $70 Million to Enhance Robotic Blood Collection

Vitestro, a Netherlands-based innovator in medical robotics, has successfully raised $70 million in a Series B funding round. The company, known for its development of autonomous blood-drawing technology, is set to use this capital to further its phlebotomy platform, the Aletta Autonomous Robotic Phlebotomy Device, and prepare for broader commercial deployment.

Investors and Strategic Partnerships

The Series B round saw participation from a diverse group of investors, including healthcare institutions and venture funds. Notable participants are Labcorp Venture Fund, Mayo Clinic, Sutter Health, InterVest, MGFO, PGGM, Puma Venture Capital, ROM Utrecht, Invest-NL, EIC Fund, Fred Moll, NYBC Ventures, and Sonder Capital.

Company Leadership

Vitestro was co-founded by CEO Toon Overbeeke and Brian Joseph, who serves as the Commercial Director. Overbeeke expressed the company's vision, stating: "Our mission is to establish a new standard in autonomous robotic venous access and diagnostic blood collection."

Expansion and Technological Advancements

The funding will be pivotal in advancing the next generation of Vitestro's Aletta system, which aims to automate blood collection by utilizing robotics, multimodal imaging, and artificial intelligence. This technology is designed to improve the precision and consistency of blood draws, thereby enhancing the patient experience and operational efficiency in clinical settings.

Regulatory and Market Expansion

Currently, the Aletta system holds a CE mark in Europe and is being utilized in clinical and pre-commercial settings across the region. Vitestro is working on gaining FDA approval in the United States through the De Novo regulatory pathway. This step is crucial for the company as it plans to expand its presence in the U.S. market.

Use of Funds

The raised capital will support several strategic initiatives:

  • Product Development: Further enhancement of the Aletta system to meet evolving clinical needs.
  • Clinical Studies: Expansion of clinical trials to validate the system's efficacy and safety across different healthcare environments.
  • Manufacturing Scale-up: Increasing production capacity to meet anticipated demand as the company moves towards broader commercialization.
  • Integration and Collaboration: Working with healthcare providers to integrate the system into existing clinical workflows and technology infrastructure.

Future Outlook

With the new funding, Vitestro is well-positioned to continue its growth trajectory and make significant strides in the field of autonomous blood collection. By addressing staffing shortages and reducing variability in manual procedures, the company aims to set a new benchmark in phlebotomy practices globally.

As the company moves forward, it remains committed to its goal of improving the quality and efficiency of diagnostic blood collection worldwide.